Johnson & Johnson

Yahoo Finance • yesterday

Bullish Two Hundred Day Moving Average Cross - O

In trading on Friday, shares of Realty Income Corp (Symbol: O) crossed above their 200 day moving average of $57.44, changing hands as high as $57.50 per share. Realty Income Corp shares are currently trading up about 1.1% on the day. Th... Full story

Yahoo Finance • yesterday

Is There Still Value in J&J After Shares Jumped 44% in 2025?

Wondering if Johnson & Johnson stock is a hidden gem or already fully priced? This article will break down everything you need to know about its current value. The share price recently moved up by 11.2% over the last month, contributing to... Full story

Yahoo Finance • 2 days ago

The ‘Anti-Mag 7’ ETF Is Up 12% and Looks Ready To Run

LumineImages / iStock Quick Read The Defiance Large Cap ex-Mag 7 ETF (XMAG) posted a 13.54% return year-to-date by excluding the Magnificent 7 stocks from the S&P 500. XMAG outperformed the calculated 7% return of the S&P 500 without the... Full story

Yahoo Finance • 2 days ago

This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside – Here’s Why

We recently published 10 Best Small-Cap Stocks With Huge Potential According to Reddit as Market Looks Beyond AI Trade. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is among the best small-cap stocks to buy according to Redditors. Halozyme T... Full story

Yahoo Finance • 3 days ago

Nanotechnology Drug Delivery Market Projected to Reach USD 200.77 Billion by 2032, Owing to Prevalence of Chronic Diseases & Advances in Nanomedicine – SNS Insider

Austin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Nanotechnology Drug Delivery Market Size & Growth Analysis According to a SNS Insider, the Nanotechnology Drug Delivery Market size was valued at USD 96.39 billion in 2024 and is projected to re... Full story

Yahoo Finance • 4 days ago

Is Kenvue’s Share Price a Bargain After 13.5% Jump and New Product Launches?

Ever wondered if Kenvue is a hidden value play or if its recent price is telling us something different? Today, we are unpacking whether the current share price is a bargain or a warning sign for investors. Kenvue’s stock price has caught... Full story

Yahoo Finance • 4 days ago

Johnson & Johnson (JNJ): Exploring Valuation Perspectives After Recent Share Price Momentum

Johnson & Johnson (JNJ) shares have edged higher over the past month, building on a steady run that has seen the stock advance 17% in the past 3 months. Investors are watching for what comes next as momentum builds. See our latest analysi... Full story

Yahoo Finance • 4 days ago

As Alphabet nears $4T, here are top 10 healthcare stocks by marketcap

[Stethoscope and US dollar banknotes on chart or graph paper, Financial, account, statistics and business data medical health concept.] manassanant pamai/iStock via Getty Images Alphabet (GOOG [https://seekingalpha.com/symbol/GOOG]) (GOOG... Full story

Yahoo Finance • 5 days ago

If You Invested $10K In Johnson & Johnson Stock 10 Years Ago, How Much Would You Have Now?

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Johnson & Johnson (NYSE:JNJ) is a global healthcare company that develops, manufactures, and sells pharmaceutical products and medical de... Full story

Yahoo Finance • 5 days ago

Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook

Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty (“HCRx”) of a non-dilutive royalty financing valued up to $71 millionProgress in the JNJ-1900 (NBTXR3) global development prog... Full story

Yahoo Finance • 5 days ago

NANOBIOTIX fait le point sur sa trésorerie et son activité opérationnelle du troisième trimestre 2025 et partage des perspectives cliniques pour 2026

Base financière posée dans la perspective d’une autonomie financière et d’une croissance à long-terme via la finalisation de l’accord de financement non-dilutif de partage de redevances (royalty financing) avec HeathCare Royalty (« HCRx »)... Full story

Yahoo Finance • 5 days ago

EXCLUSIVE: Sustainable Value Creation: Keynote Fireside with Trian Fund Management, 5th Palm Beach CorpGov Forum

CorpGov and IPO Edge are pleased to provide complete video coverage of the fifth annual Palm Beach CorpGov Forum held on Nov. 5-6, featuring keynote speaker Josh Frank, Partner and Co-Chief Investment Officer at Wall Street legend Nelson... Full story

Yahoo Finance • 5 days ago

Hip Replacement Market Competitive Landscape Report 2025: Recent Developments, Strategies, Sustainability, Product Launches, Key Persons, and Revenue Forecasts

Company Logo The Hip Replacement industry is poised for substantial growth, projected to reach US$ 10.24 billion by 2033, up from US$ 6.92 billion in 2024, at a CAGR of 4.45% between 2025 and 2033. This expansion is driven by increased aw... Full story

Yahoo Finance • 5 days ago

RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum

BRIDGEWATER, N.J., Nov. 24, 2025 /PRNewswire/ -- RVL Pharmaceuticals, Inc and its affiliates (together, "RVL") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerat... Full story

Yahoo Finance • 5 days ago

Johnson & Johnson Reaches Analyst Target Price

In recent trading, shares of Johnson & Johnson (Symbol: JNJ) have crossed above the average analyst 12-month target price of $175.77, changing hands for $176.64/share. When a stock reaches the target an analyst has set, the analyst logica... Full story

Yahoo Finance • 5 days ago

Johnson & Johnson To Discontinue Autonomy Study

(RTTNews) - Johnson & Johnson has decided to discontinue the Autonomy study as a scheduled review found posdinemab did not achieve statistical significance in slowing clinical decline. The Autonomy proof-of-concept study was a first-of-its... Full story

Yahoo Finance • 6 days ago

Jim Cramer Dissects Kimberly-Clark’s Acquisition of Kenvue

Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently offered insights on. Cramer discussed the company’s planned acquisition of Kenvue during the episode. He said: “Alright, this is one we’ve talked about a bun... Full story

Yahoo Finance • 6 days ago

2 World Class Funds That Avoid The AI Bubble and Mag 7 Stocks

marcouliana / iStock via Getty Images Quick Read The S&P 500 gained 16% year-to-date but over 50% of that gain came from the Magnificent 7 tech stocks. Independent Franchise Partners US Equity (IFPUX) returned 23.23% year-to-date with Or... Full story

Yahoo Finance • 6 days ago

SA: What are the best defensive stocks right now?

[Portfolio management and asset allocation concept : Dollar bag, financial products on balance scale e.g ETFs, REITs, stocks, commodities, bonds, mutual funds, depicts balancing between risk and return] William_Potter What are the best de... Full story

Yahoo Finance • 6 days ago

Notable healthcare headlines for the week: Abbott, Medtronic, Merck and J&J in focus

Wall Street staged a rebound on Friday, closing the session in positive territory after a turbulent, tech-driven downturn rattled the Nasdaq Composite just a day earlier. Friday's market boost was supported by reports that the Trump admin... Full story